GRAIL, Inc.

NASDAQ:GRAL

Medical - Diagnostics & Research

Healthcare
$102.10 +3.20%

+$1.90 today

Market cap
$4.59B
Beta
3.16
P/E (TTM)
-6.3
EPS (TTM)
-$9.73
52W Low $29.95High $118.84

Volume 0.62M

Average 0.77M

GRAL Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

GRAIL, Inc.NASDAQ: GRAL

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) growth accelerates

Q2 FY2026 weighted avg shares (diluted) of 43.11M shares rose 23.0% year over year, ahead of the +20.6% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 6.1% from the prior quarter. Over 3 fiscal years it compounded at +5.8% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +23.0% holds above the trailing-twelve-month pace of +20.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
43.11M+6.1% QoQ
Last fiscal yearDec 2025
36.75M+15.2% YoY
LTMJun 2026
40.15M+20.6% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+23.0%——
1 year+15.2%——
3-year CAGR+5.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
36.75M USD
Year-over-year change
+15.2%
4-year CAGR
+4.3%

Weighted Avg Shares (Diluted) vs competitors

How GRAL compares with its peers on the latest reported figures

  • GRAL's LTM Jun 2026 weighted avg shares (diluted) of 40.15M shares is the 7th highest of the 10 companies compared; the peer median is 93.15M shares.
  • Its year-over-year change of +20.6% is the 2nd highest of 10, against a peer median of +2.4%.
  • Over three fiscal years its annual growth of +5.8% compares with a peer median of +6.0%.
GRAL Competitors Peer median
Weighted Avg Shares (Diluted) for GRAL and competitors
Company Period LTM YoY 3-year CAGR
NTRANatera, Inc.LTM Jun 2026139.67M +7.5%+11.6%
GHGuardant Health, Inc.LTM Sep 2026131.61M +5.9%+7.1%
NEONeoGenomics, Inc.LTM Jun 2026129.14M +1.5%+1.0%
PSNLPersonalis, Inc.LTM Mar 202693.42M +36.5%+25.0%
MYGNMyriad Genetics, Inc.LTM Mar 202693.15M +2.4%+5.0%
BLLNBillionToOne, Inc.LTM Jun 202649.5M +10.7%—
GRALGRAIL, Inc.LTM Jun 202640.15M +20.6%+5.8%
FLGTFulgent Genetics, Inc.LTM Mar 202630.81M +1.0%-0.2%
CSTLCastle Biosciences, Inc.LTM Mar 202629.46M +0.8%+3.6%
WGSGeneDx Holdings Corp.LTM Jun 202628.68M +2.4%+38.0%
Peer median (excluding GRAL) 93.15M+2.4%+6.0%

Competitors are the stored peer set for GRAL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue14.61M55.55M93.11M125.6M147.17M
Cost of Revenue114.62M172M188.72M203.62M209.75M
Gross Profit(100M)(116.45M)(95.61M)(78.02M)(62.57M)
Gross Margin-684.4%-209.6%-102.7%-62.1%-42.5%
Research & Development460.21M329.58M338.75M322.38M195.79M
Selling, General & Admin234.06M296.44M362.56M367.82M275.8M
Operating Expenses1.17B5.33B1.42B2.11B471.59M
Depreciation & Amortization58.45M154.76M158.7M158.06M156.34M
EBITDA(1.21B)(587.7M)(638.22M)(610.17M)(378.16M)
EBITDA Margin-8259.0%-1058.0%-685.5%-485.8%-257.0%
Operating Income(1.27B)(5.44B)(1.52B)(2.19B)(534.16M)
Operating Margin-8659.6%-9798.2%-1627.6%-1743.0%-363.0%
Interest Income332K1.74M7.95M26.73M28.65M
Interest Expense00000
Other Income / Expenses90K1.5M7.75M26.8M(341K)
Income Before Tax(1.27B)(5.44B)(1.51B)(2.16B)(534.5M)
Pre-Tax Margin-8659.0%-9795.5%-1619.3%-1721.7%-363.2%
Income Tax Expense(17.48M)(42.29M)(41.95M)(135.36M)(126.15M)
Net Income(1.25B)(5.4B)(1.47B)(2.03B)(408.35M)
Net Margin-8539.4%-9719.3%-1574.2%-1613.9%-277.5%
EPS (Basic)(40.18)(173.87)(47.20)(63.54)(11.11)
EPS (Diluted)(40.18)(173.87)(47.20)(63.54)(11.11)
Weighted Avg Shares31.05M31.05M31.05M31.9M36.75M
Weighted Avg Shares (Diluted)31.05M31.05M31.05M31.9M36.75M

GRAIL, Inc.

NASDAQ:GRAL

Intrinsic Alpha fair value

Locked

Current Price

$102.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.